Capricor Theraputics Q4 revenue falls to zero, net loss widens

Overview

• U.S. biotech reported Q4 revenue of $0, down from prior year as milestone revenue fully recognized

• Q4 net loss widened yr/yr on higher operating expenses

• Company ended 2025 with $318 mln cash, expects runway through 2027

Outlook

• Capricor expects cash balance to support operations through 2027

• Company expanding manufacturing capacity in anticipation of potential Deramiocel approval

Result Drivers

• REVENUE DECLINE - Co said Q4 revenue fell to zero as all milestone and upfront payments from Nippon Shinyaku were fully recognized by end-2024

• Cash, cash equivalents and marketable securities totaled approximately $318.1 million as of December 31, 2025

• HIGHER OPERATING EXPENSES - Co attributed increased Q4 operating expenses to ongoing clinical development, regulatory activities, and commercial launch preparations

Company press release: ID:nGNX27Zfp8

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Capricor Therapeutics Inc is $50.00, about 48.9% above its March 11 closing price of $33.57

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.